Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors
HPD occurred in about 20% of BM patients receiving ICI. More research is necessary to prospectively analyze the occurrence of HPD and identify predictive factors for HPD in BM patients.
Authors
- Charissa Jessurun (ORCID: https://orcid.org/0000-0002-9569-1515)
- Timothy R. Smith (ORCID: https://orcid.org/0000-0003-1976-0766)
- Francesca Siddi (ORCID: https://orcid.org/0000-0002-0844-9289)
- Marike L. D. Broekman (ORCID: https://orcid.org/0000-0002-0226-0119)
- Yu Tung Lo (ORCID: https://orcid.org/0000-0002-4234-8991)
- Alexander Hulsbergen (ORCID: https://orcid.org/0000-0002-1869-5352)
- Noah Nawabi
- Rohan Jha
Institutions
- University of Verona (IT)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Leiden University Medical Center (NL)
- Massachusetts General Hospital (US)
- Medisch Centrum Haaglanden (NL)
Publication Details
- Journal
- Journal of Neuro-Oncology
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1007/s11060-025-04955-9
- Citations
- 2
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04